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MACROPHAGE CD163 EXPRESSION IS NEUROPROTECTIVE 
 
IN SUBARACHNOID HEMORRHAGE PATIENTS 
 
RUIYA CHEN 
ABSTRACT 
Background: 
 
 Subarachnoid Hemorrhage (SAH) accounts for 3-5% of total stroke patients 
annually. Despite its rare incidence, SAH carries a 50% mortality rate. Survivors are 
often left with varying degrees of disability, many will never return to their previous jobs 
and require long-term care. One of the leading causes for this high mortality and 
morbidity rate in SAH is Delay Cerebral Ischemia (DCI). Researchers are now beginning 
to investigate neuroinflammation as the underlying cause for DCI. Studies have shown 
the activation of the innate immune system in the central nervous system is initiated by 
excess hemoglobin in the subarachnoid space. This process is mediated by the Toll-Like 
Receptor 4 expressed on the tissue-resident macrophages. Activated macrophages release 
pro-inflammatory cytokines and cause neuronal apoptosis in the surrounding tissue. 
However, macrophages may also mediate neuroprotection in SAH. A macrophage 
surface receptor called CD163 is responsible for the recognition and endocytosis of 
excess hemoglobin. The thesis provides a closer assessment of the neuroprotective role of 
macrophages in SAH patients. 
 
Methods:   
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Cerebrospinal fluid (CSF) was obtained from twenty three patients diagnosed 
with SAH (on day 1 and day 7 post-admission) or unruptured aneurysms. Immune cells 
were separated from CSF and analyzed by flow cytometry. The following antibody panel 
was used in this study: PE-anti-CD163, PeCy7-anti-CD15, and APC-anti-CD14. 
Macrophage expression of CD14 and CD163 was quantified using FlowJo. 
SAH patients were graded by the Hunt and Hess scale for the clinical states upon 
admission; modified Fisher scale for the size of the hemorrhage; and modified Rankin 
scale for clinical outcome at the time of discharge. 
 
Results: 
 Significant increase in macrophage CD14 and CD163 expression is observed in 
day 1 SAH patients (p<0.05) as compared to the control group. Male SAH patients have 
equivocal macrophages CD163 expression on day 1 as compared to the control group 
(p>0.05), and significantly higher expression on day 7 as compared to day 1(p<0.05). 
Female SAH patients have significantly higher macrophages CD163 expression on day 1 
as compared to control patients (p<0.05), but slightly decreased expression on day 7 as 
compared to day 1(p>0.05).  
 Lower macrophages CD163 expression is observed in SAH patients with more 
severe hemorrhage (marked by higher modified Fisher score), but not in patients with 
more severe clinical states at admission (marked by higher Hunt and Hess score). 
Furthermore, SAH patients with low day 1 macrophage CD163 expression and low 
expression on day 7 may be correlated with better clinical outcome (marked by lower 
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modified Rankin score). However, more patients are required before correlation can be 
established.  
 
Conclusion: 
 The data further support our previous findings in mouse SAH model that 
macrophages in the central nervous system may mediate inflammation via the increased 
expression TLR4, measured by increased expression of its co-receptor CD14. 
Macrophages also may be neuroprotective, mediated by increased expression of CD163 
in SAH patients. The macrophage CD163 expression may be the key in determining 
clinical outcome in SAH patients, but additional patients are required to establish 
statistical significance.  
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INTRODUCTION 
CENTRAL NERVOUS SYSTEM REVIEW 
Meninges and Subarachnoid space review 
The meninges layers, located internal to the neurocranium, envelop the brain and 
play a critical role in the homeostasis of the brain by providing nourishment and 
protection against mechanical injury. The meninges layers are divided into three 
membranous sub-layers: a thick fibrous membrane located directly adjacent to the skull 
called the dura mater, a spider web-like fibrous membrane called the arachnoid mater, 
and a delicate, thin membrane that adheres to the surface of the brain called the pia mater. 
The subarachnoid space (SAS) is a cavity between the arachnoid mater and pia mater. 
This anatomical space is composed of wide intervals called the cisterns, and a collagen 
tissue called the trabeculae that extends from the arachnoid mater into the pia mater 
(Morris, 1893). Cerebrospinal fluid (CSF) freely flows through a series of 
intercommunicating channels in the ventricular system and the SAS (Saboori & Sadegh, 
2015). By flowing through the SAS surrounding the brain, the CSF acts as a physical 
cushion against mechanical stress, provides nutrients including glucose, and provides 
immunological protection by carrying immune cells.  Cerebral arteries and cortical veins 
traverse through the SAS before reaching to the brain tissue or draining into the cranial 
venous sinuses (Voron, 2007).  
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Cerebral Circulation Review 
Blood travels up along the neck and enters the brain via a series of large arteries: 
the internal carotid arteries and the vertebral arteries. The vertebral arteries join at the 
base of the skull and form the basilar artery. The basilar artery gives rise to a pair of 
posterior cerebral arteries. The internal carotid arteries branch into the anterior 
cerebral arteries and middle cerebral artery (MCA). The anterior and posterior 
communicating arteries connect the anterior, middle and posterior cerebral arteries to 
form a ring-like structure. This highly collateral circulation is called the Circle of Willis 
(CoW) (Devault et al., 2008).  In cases of developmental defects, vascular stenosis, or 
occlusion in any of these major vessels, the CoW offers some protection against ischemia 
by rerouting blood flow through the communicating arteries (Hendrikse, Hartkamp, 
Hillen, Mali, & van der Grond, 2001).  
  
Cerebrospinal Fluid Review 
CSF serves several physiological functions important to the central nervous 
system (CNS) including reducing the weight of the brain by approximately 75%, acting 
as a brain cushion to protect against head trauma (Bonadio, 2014), and helping to 
maintain homeostatic intracranial pressure (ICP) levels. While ICP may fluctuate during 
the course of the day due to posture changes, the cardiac cycles, and the daily production-
absorption cycles of CSF (Daley et al., 1982), the human brain can tolerate a narrow 
range of ICP fluctuation before injury occurs. Untreated acute elevation of ICP, generally 
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defined as an increase of ICP greater than 10-20mmHg for more than 5 minutes, may 
lead to brain herniation or ischemia, possibly result in death. (Roytowski, 2013). 
Approximately 80% of the CSF is produced by the choroid plexus, an extension 
of the ependymal layer of the lateral, third and fourth ventricles (Damkier, Brown, & 
Praetorius, 2013). CSF travels along the ventricular system and subsequently enters the 
SAS. CSF in the brain is mainly drained via the arachnoid villi and granulation tissue, 
which are small protrusions into the dural-venous sinus that allow for unidirectional flow 
of CSF (Wright, Lai, & Sinclair, 2012); a small fraction of the CSF in the spinal cord is 
drained through the spinal nerve sheath (Laterra J, 1999). CSF in an average adult is 
replaced three to four times a day; the dynamic flow of CSF acts as an excellent medium 
for which nutrients and metabolites can be exchanged between the CNS and systemic 
circulation system (Damkier et al., 2013). Critical biological molecules such as oxygen, 
carbon dioxide, and glucose are absorbed directly through the highly selective blood 
brain barrier (BBB).  Other biological molecules such as calcium and some hormones 
such as insulin-like growth factor-II, are absorbed or produced into the CNS via the 
blood-CSF barrier, which is regulated by the epithelial cells and the tight gap junctions of 
the choroid plexus (Laterra J, 1999). In addition, CSF is involved in the clearance of 
neurotransmitter metabolites, such as homovanillic acid and 5-hydroxyindoleacetic acid, 
acts as the lymphatic drain, and plays an important role in the local immune system by 
regulating entries of lymphocytes and innate immune cells into the CNS  (Laterra J, 
1999).  
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Despite being very similar to the blood plasma, CSF of a healthy individual has a 
significantly decreased concentration of proteins such as albumin, transferrin and 
immunoglobulin, and approximately 10,000x fewer leukocytes per microliter 
(Felgenhauer, 1974; Sofronescu, 2015). CSF can exchange nutrients and waste products 
with the interstitial fluid of the brain with minimum hindrance due to the leaky 
ependymal cells. Therefore, CSF analysis is often used in combination with other 
imaging test in diagnosing a wide arrange of diseases in the CNS, including meningitis, 
brain tumor, multiple sclerosis (MS) and subarachnoid hemorrhage (Seehusen, Reeves, & 
Fomin, 2003).   
 
STROKE REVIEW 
 From 1999 to 2008, approximately 795,000 American suffered from a stroke 
annually. This translated to 130,000 deaths each year, making stroke the fifth leading 
cause of death in the United States. According to a 2016 report issued by the Centers for 
Disease Control and Prevention, 87% of stroke patients suffered from ischemic stroke, 
while 10% from intracerebral hemorrhage, and the rest from subarachnoid hemorrhage. 
Stroke has caused the United States economy an estimated $33 billion from 2011-2012, 
including direct costs such as healthcare services, medications, and short term care; and 
indirect cost such as loss of productivity and long-term care (Mozaffarian et al., 2015).  
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Subarachnoid Hemorrhage Review 
Subarachnoid hemorrhage (SAH) is a specific type of intracranial hemorrhage, 
where blood bleeds into the SAS due to trauma or rupture of aneurysm. Aneurysmal SAH 
accounts for 2%-5% of total stroke patients and nearly 85% of all non-traumatic SAH 
patients each year (van Gijn & Rinkel, 2001). Despite its low incidence rate in the 
general population, SAH deserves particular interest due to its prevalence among relative 
younger age group in comparison to other stoke victims, and carries a high morbidity and 
mortality rate in comparison. Half of the American suffer from SAH annually are at or 
under the age of 55, compared to the mean age of 69 years-old for intracerebral 
hemorrhage (Rincon & Mayer, 2013). Approximately 12-15% of the SAH patients will 
die before reaching to the hospital (Connolly et al., 2012), and nearly 50% will not 
survive pass the first 30-days post-ictal. In fact, almost one third of premature deaths 
before the age of 65 due to stroke each year are attributed to SAH (Johnston, Selvin, & 
Gress, 1998). For those who survive the ictal event, 42% will never return to their 
previous occupations or will require long-term care due to neurological or cognitive 
impairments (Reinhardt, 2010). Despite early detection and better care, morbidity and 
mortality for SAH have not improved significantly for the past three decades (Sodhi et 
al., 2014).   
Etiology review 
Aneurysmal SAH occurs when an intracranial aneurysm is ruptured. An aneurysm 
can form in localized regions of arteries or veins, where the vascular wall is weakened 
due to poorly understood mechanisms. The resulting aneurysm can often be identified on 
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an angiogram via its characteristic balloon-like appearance. Aneurysms are classified 
according to their pathology into dissecting aneurysm, fusiform aneurysm or saccular 
aneurysm. As the most common intracranial aneurysm, saccular aneurysm is also referred 
to as the “berry aneurysm” and are commonly found in the CoW, usually at the  
bifurcation points of major blood vessels (Brisman, 2014). Most adults with saccular 
aneurysms are asymptomatic until one of these aneurysms ruptures. The complete 
etiology of SAH remains controversial among researchers. However, large cohort studies 
have found that women are 1.6 times more susceptible to SAH than men, and African 
Americans are 2.1 times more susceptible than white (Suarez, Tarr, & Selman, 2006). 
Other studies have linked certain modifiable behaviors, such as smoking, hypertension, 
drug and alcohol abuse, to the incidence of SAH (Broderick et al., 2003; Kissela et al., 
2002). In addition, certain hereditary or congenital diseases, such as autosomal dominant 
polycystic kidney disease, Type IV Elhers-Danlos syndrome, pseudoxanthoma elasticum, 
and fibromuscular dysplasia, have been linked to increase risk of SAH (NINDS, 2013; 
Suarez et al., 2006). Individuals with multiple intracranial aneurysms, family history of 
SAH, or have been treated previously for ruptured aneurysms are also at higher risk of 
developing SAH (Bederson et al., 2009). The location and size of the aneurysms also has 
an effect on the incidence of SAH. Nearly 90% of all saccular aneurysms are found in the 
anterior circulation of the CoW: 30-40% of which are found in the anterior cerebral 
artery – anterior communicating artery complex; 30% around the internal carotid 
arteries, including posterior communicating, ophthalmic, and terminus arteries; and 30% 
at the middle cerebral artery (Knopman, 2012). The five-year cumulative risk of 
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aneurysm burst in the anterior and posterior cerebral circulation is summarized in Table 
1 (Wiebers et al., 2003).  
Size Anterior circulation Posterior circulation 
<7mm 0% 2.5% 
7mm – 12mm 2.6% 14.5% 
13mm – 24mm 14.5% 18.4% 
>25mm 40% 50% 
Table 1. Five year cumulative risk analysis for aneurysmal rupture (Wiebers et al., 
2003). 
 
Diagnosis and Treatment 
SAH patients often complain of having the “worst headache ever” around the time 
of the ictal event.  Additional symptoms of SAH may include nausea, vomiting, neck 
pain, photophobia or other vision problems, decreased or loss of consciousness, sudden 
confusion or irritability, and seizures (Suarez et al., 2006). In lieu of the classical 
symptom, SAH may be diagnosed by head computer tomography (CT) scan, which has a 
90% sensitivity for SAH within 24 hours of symptom onset (Sames, Storrow, Finkelstein, 
& Magoon, 1996).  For patients with negative CT scans, additional tests including lumbar 
puncture (LP) may be used. SAH diagnoses can also be confirmed by elevated opening 
pressure during LP, red blood cell (RBC) count and xanthochromia in the CSF. 
Xanthochromia is the yellow discoloration in CSF, caused by the accumulation of 
bilirubin, a breakdown product of hemoglobin. Other imaging tests such as contrast CT 
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angiography or MRI may be used if previous tests failed to detect the bleed in suspected 
SAH patients (Suarez et al., 2006).  
Two grading systems are currently used to grade SAH patients at admission. The 
modified Fisher scale, based on the original Fisher scale developed in 1980, categorizes 
patients based on the extent of hemorrhage on CT scans, as well as the presence of 
cisternal hemorrhage (Frontera et al., 2006). The Hunt and Hess scale, developed in 1968, 
describes the clinical state of the SAH patients (Hunt & Hess, 1968). Both grading 
system have shown correlation with two-year clinical outcome in SAH patients (Lindvall, 
Runnerstam, Birgander, & Koskinen, 2009).  
Currently, surgical treatments for SAH include endovascular coil embolization or  
direct clipping depending on the characteristic of the aneurysm (Suarez et al., 2006). 
Direct aneurysmal clipping requires an open skull surgery where a metal clip is used to 
secure the aneurysm at the base. Aneurysms in the MCA are often treated by this surgical 
procedure due to their inaccessibility by the endovascular method. Endovascular coil 
embolization uses a catheter guided wire through the artery of patient’s groin to the 
location of the aneurysm, and effectively exclude the aneurysm from the circulation by 
inducing thrombosis (Bederson et al., 2009).  Aneurysms in the posterior circulation are 
more likely to be treated by the coiling method. However, there is no general consensus 
in the preferred surgical procedure. Several randomized controlled studies have found the 
coiling method to produce more favorable outcome at 1-year post-operation despite risk 
of re-bleeding is higher (Bederson et al., 2009; Lanzino, Murad, d'Urso, & Rabinstein, 
2013). The results are confounded by the facts that treatment assignments are often 
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affected by hospital preferences, locations of the aneurysm, and pre-operative conditions 
of the patients; therefore these studies are not truly randomized (Li et al., 2013). In fact, 
the only large randomized clinical trial by the International Subarachnoid Aneurysm Trial 
excludes more than 80% of the patients from study based on the aforementioned criteria, 
and as a results, any conclusion may only apply to a very limited patients pool among the 
SAH population.  
For patients who develop hydrocephalus, an external ventricular drain (EVD) is 
placed in the skull to drain the excess CSF to relieve the ICP. Clinical treatments have 
been focused on hemodynamic augmentation therapy, with some success, to prevent the 
development of delayed cerebral ischemia (DCI). In the past, it was common to manage 
SAH patients with the triple H therapy (induced hypertension, hypervolemia, and 
hypervolemia). However, there were equivocal evidence showing improved outcome 
associated to the therapy, while the treatment has many detrimental side effects to the 
patients (Lee, Lukovits, & Friedman, 2006). As such, euvolemia and induced 
hypertension are now the recommended therapeutic treatments for SAH patients 
(Connolly et al., 2012). In addition, oral administration of nimodipine remains to be the 
only effective drug treatment proven to effectively improve neurological outcome in the 
last three decades. Nimodipine is a dihydropyridine calcium channel blocker that not only 
reduces cerebral vasospasm, but is thought to have neuroprotective effects as well via 
unknown mechanisms (Dabus & Nogueira, 2013).  
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Complications 
 One of the leading causes for high morbidity for patients who survive the initial 
hemorrhage is Delayed Cerebral Ischemia (DCI), which develops on day 3-14 in 30% of 
the survivors (Vergouwen et al., 2010). Researchers have long believed that cerebral 
vasospasm, or the narrowing of the cerebral arteries, was the main cause of DCI. Studies 
were focused on prevention and treatment of vasospasm as a mean to reduce the risk of 
DCI development despite controversial statistics supporting the hypothesis. However, 
meta-analysis revealed that of the 70% of SAH patients who developed vasospasm, only 
30% would eventually developed DCI, while 21% of patients developed DCI 
independently of cerebral vasospasm (Sehba, Pluta, & Zhang, 2011). Furthermore, a 
series of clinical trials conducted by MacDonald et al. in 2012 demonstrated that effective 
treatment of vasospasm showed no significant improvement on patient outcome 
(Macdonald et al., 2012). Meanwhile, several promising studies have suggested the Early 
Brain Injury (EBI), specifically neuroinflammation, potentially plays a significant role in 
the DCI pathogenesis (Crowley, Medel, Kassell, & Dumont, 2008).  
 EBI describes the pathophysiological changes that occur within the first 72 hours 
following an aneurysm rupture. Immediately following the ictal event, there are an acute 
increase in ICP and decrease in cerebral blood flow (CBF) that are proportional to the 
volume of the hematoma. The increase in ICP will often result in global ischemic injury 
regardless of the severity of the bleed. Studies show that the extent of increased ICP or 
reduced CBF are good indicators of mortality (Cossu, Messerer, Oddo, & Daniel, 2014). 
Secondary to the global ischemic injury, widespread apoptosis is observed in the 
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hippocampus and the BBB, which further exacerbate the injury (Cahill, Calvert, & 
Zhang, 2006). Perhaps more importantly, the release of blood into the subarachnoid space 
has been shown to activate the innate immune system, resulting in a sterile inflammation 
of the brain, or neuroinflammation.   
 The blood-induced inflammation is mediated by the release of free hemoglobin 
and its constituents into the SAS. RBCs are normally confined to the vascular system, 
protected from the SAS by the BBB or Blood-CSF barrier. However, after an aneurysmal 
rupture, RBCs are released into the SAS and lysed within hours (Turgeon, 2005). Excess 
hemoglobin in this anatomical space can exacerbate neuronal injury via several 
mechanisms. First, hemoglobin is one of the major contributors to the production of 
superoxide anion and hydrogen peroxide, which in turns may generate free radicals. 
Excess free radicals have a deleterious effect on neuronal, glial and endothelial cells by 
activating the apoptosis and necrosis pathway (Ayer & Zhang, 2008). Second, 
hemoglobin acts as a pro-inflammatory stimulus, demonstrated by the increase release of 
TNF-α, upregulation of ICAM-1, VCAM-1 and E-Selectin on endothelial cells in animal 
models of SAH (Vecchione et al., 2009). The upregulation of these molecules activate 
specific peripheral leukocytes, in addition to increase the vascular permeability which 
allows for leukocytes extravasation across the BBB into the CNS. Finally, hemoglobin 
can activate the innate inflammatory cascade in macrophages directly. Heme, the major 
constituent of hemoglobin, is recognized by the Toll-Like Receptor 4 (TLR4) on 
microglia, or the tissue-resident macrophages (Figueiredo et al., 2007), Several studies, 
including those of our lab, have shown that TRL4 activations are necessary and sufficient 
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to cause a sterile neuroinflammation in the brain (Figueiredo et al., 2007; Lin et al., 
2012).  
 
NEURO-INFLAMMATION  
The CNS was considered as an immune privilege site in the past: many believed 
that the CNS was isolated from the peripheral immune system by the BBB. However, 
evidences have emerged in the last two decades suggest that the CNS is under constant 
surveillance by tissue-resident macrophages. Furthermore, the CNS is also actively 
communicating with the peripheral immune system. In fact, neuroinflammation plays a 
vital role in the pathology of many neurodegenerative diseases, including MS, 
Parkinson’s disease and Alzheimer’s disease. (Carson, Doose, Melchior, Schmid, & 
Ploix, 2006). Post-modem immunohistochemistry analysis of human brains often show 
differentiation and proliferation of the tissue-resident macrophages (Pey, Pearce, 
Kalaitzakis, Griffin, & Gentleman, 2014; Vogel et al., 2013).  
 In SAH, several classical pro-inflammatory molecules, such as c-reactive protein 
(CRP), tumor-necrosis factor α (TNF-α), interleukin 1 (IL-1), interleukin 6 (IL-6), and 
interleukin 8 (IL-8) have been documented to increase in the CSF of patients by many 
studies. Many of these inflammatory molecule are associated with poor neurological or 
cognitive outcome (Hong et al., 2014). TNF-α, for example, is produced by the activated 
macrophages and is responsible for fever induction, oxygen radical production, 
upregulation of adhesion molecules on endothelial cells and activation of peripheral 
leukocytes. Inhibiting TNF-α activities by injecting infliximab, an anti-TNF-α antibody, 
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in a mouse SAH model is sufficient to attenuate neuronal damage (Vecchione et al., 
2009). The same study has also shown that endothelial expression of VCAM-1, ICAM-1 
and selectin increase dramatically at the site of injury after SAH induction. These 
signaling molecules will bind to their corresponding ligands expressed on the surface of 
circulating myeloid cells, and initiate the processes for adhesion and extravasation across 
the BBB. In fact, neuronal deaths in a rat model of SAH have been strongly linked with 
the activation and infiltration of macrophages into the CNS (Kooijman et al., 2014). 
Therefore, it is not surprising that neuroinflammation has been gaining recognitions as 
one of the potential causes to poor outcome in SAH patients.  
 
Innate Immune Response Review 
 In order to effectively attenuate the detrimental effects caused by the 
aforementioned inflammatory response, one must first investigate the key players involve 
in neuroinflammation. The blood products released by the ruptured aneurysm have been 
identified as the instigator of the innate immune response by many studies. This is either 
accomplished by the direct recognition of hemoglobin by TLR4, or indirectly via the 
generation of reactive oxygen species (ROS), free radicals, and nitric oxide (NO) by 
hemoglobin. Two populations of macrophage of distinct embryonic origins are thought to 
mediate this blood-induced inflammatory response. Macrophages are large mononuclear 
cells that surveil the blood and tissue. They are capable of differentiation between “self” 
and “foreign” substances via a variety of surface receptors, including Toll-Like Receptors 
(TLRs), nucleotide-binding oligomerization domains (NODs)-like receptors, and various 
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scavenger receptors (Cherry, Olschowka, & O'Banion, 2014). “Foreign” substances such 
as microbes, damaged cells, tumor cells, and tissue-graft that carry specific motifs which 
can be recognized by any of the aforementioned receptors will activate the macrophages 
to engulf the substances in a process called phagocytosis. Macrophages also release a 
wide variety of signaling molecules depending on the stimuli, and accordingly perform 
different sets of very specific physiological function. Furthermore, macrophages may act 
as antigen presenting cells (APCs) to activate lymphocytes in the adaptive immune 
system (Unanue, 1984). 
 
Circulating Macrophages and Tissue-Resident Macrophages 
Macrophages are often categorized into two populations based on their origins 
and distinct physiological functions. Macrophages in the peripheral immune system, 
including some tissue-resident macrophages in the skin and guts, are classified as bone 
marrow-derived macrophages (BMMs). Originated from hematopoietic stem cells 
(HSCs) in the bone marrow, BMMs constitute 10% of all nucleated cells circulating in 
the blood of a healthy individual. During inflammation, tissue-resident macrophages and 
endothelial cells release various pro-inflammatory cytokine and adhesion molecules to 
attract BMMs to the site of injury. Monocytes, the undifferentiated form of BMMs in 
blood, extravasate through the vascular wall into the injured tissue and differentiate in 
response to the cytokine presented. Differentiated BMMs share many of the phenotypic 
characteristics with activated tissue-resident macrophages, which is why monocytes have 
been thought to be the precursors of the tissue-resident macrophages in the past. 
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However, BMMs infiltration to the injured tissue will mostly disappear once injury is 
resolved, except in the case of chronic inflammation.  
Tissue-resident macrophages however, are the “permanent” population in their 
respective tissues, and maintain their populations independently via self-regeneration 
(Ginhoux & Jung, 2014). Tissue-resident macrophages are crucial to the development of 
their specific tissues, maintain homeostasis, and act as sentinels against foreign antigens; 
because of this, tissue-resident macrophages are extremely heterogeneous. Historically, 
researchers believed that tissue-resident macrophages arose from the bone marrow 
similar to the BMMs. However, recent fate mapping experiments in mouse contradict 
such view (Ginhoux et al., 2010; Hoeffel et al., 2012). Adult tissue-resident macrophages 
in mouse either originate from the erythromyeloid progenitors in the yolk sac (such as 
microglia in the CNS), or are replaced during later stages of development by fetal-liver 
monocytes (such as alveolar macrophages in the lungs), or a combination of both (such as 
Langerhans cells in the skin) (Ginhoux & Jung, 2014). Although fetal-liver monocytes 
originate from the HSCs at the aorta-gonad-mesonephros region during embryonic 
development, this should not be confused with the HSCs of which BMMs differentiated 
from. The latter does not contribute to the tissue-resident macrophage population except 
in tissues like the skin and the gut.  
Microglia deserves special attention because its adult population solely originated 
from the yolk sac. In fact, mice with genetically knock out of the colony-stimulating 
factor 1 receptor gene (csf1r) that codes for the receptor that binds to the macrophage 
colony stimulating factor (M-CSF), which is crucial for regulating macrophage 
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proliferation and differentiation, have successfully ablated most of the microglia 
population in the adult mouse brain (Ginhoux et al., 2010). Furthermore, csf1-null
 
mice, 
which contain a null mutation in the gene that codes for M-CSF, show significant brain 
defects as they matured. This suggest that microglia may play a critical role in the 
development and homeostasis of the CNS (Wynn, Chawla, & Pollard, 2013). Under 
normal homeostatic state, quiescent microglia can be identified by their ramified 
branching processes and by ionized calcium binding adaptor protein-1 (Iba-1) antibody 
fluorescence signals. Differentiation between microglia and infiltrated BMMs becomes 
more difficult during pathophysiological conditions in human, when activated microglia 
adopt many similar phenotypic characteristics found on activated BMMs (Prinz & Priller, 
2014).  
 
Macrophage Proliferation 
 Macrophages are known for their plasticity in response to a wide range of 
endogenous or exogenous stimuli. Once activated by antigen-receptor interactions, 
macrophages can change their physiology to perform a variety of functions. Traditionally 
macrophages are categorized into two distinct phenotypic populations based on their 
activation methods and cellular functions: the classically activated, pro-inflammatory 
macrophages (M1) or the alternatively activated, anti-inflammatory macrophages (M2) 
(Mosser & Edwards, 2008). However, such dichotomous view on activation models 
limits the ability to describe the in vivo actions of macrophages in many injury or disease 
model. Rather than a mutually exclusive state, evidences now suggest that macrophages 
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at any time may share many overlapping characteristics, the classical identification of M1 
vs. M2 macrophages should therefore represents the opposite end on a spectrum of 
immune response (Prinz & Priller, 2014).  
 
M1 macrophages 
The classically activated macrophages may participate in the adaptive immune 
response (induced by interferon-γ released by T-helper cells) as well as the innate 
immune response (via activation through specific surface receptors). They are the main 
effector in the elimination of foreign pathogens as well as clearance of injured tissues via 
a process call inflammation. In the innate immune response, BMMs and tissue-resident 
macrophages are activated through recognition of pathogen- or damage-associated 
molecular patterns (PAMPs and DAMPs) by surface receptors such as Toll-like, NOD-
like and RIG-I-like receptors (Mills & Ley, 2014). Once activated, M1 macrophages 
release a wide variety of inflammatory mediators. These inflammatory mediators enable 
the rapid elimination of microbes and intracellular microorganisms (such as oxidative 
species, lysosomal enzyme and TNF-α), as well as recruit and proliferate additional 
leukocytes to further drive the inflammation (such as IL-1, IL-12, and IL-23) (Mosser & 
Edwards, 2008). One of the hallmark actions of M1 macrophages is the switching of L-
arginine metabolism to the generation of nitric oxide (NO) via the action of an inducible 
nitric oxide synthase (iNOS). Overproduction of NO can damage cellular DNA and 
inhibit mitochondrial respiration in foreign organisms. Furthermore, NO may generate 
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other radicals and peroxides in target cells, which together impair many protein functions 
that are crucial to the survival of the organisms (Guzik, Korbut, & Adamek-Guzik, 2003).  
However, while the inflammatory response is crucial to the body’s defense 
against invasion, these same inflammatory mediators are also toxic to the surrounding 
tissue: their abilities to induce apoptosis and necrosis do not discriminate between foreign 
microbes and the host tissues (Mosser & Edwards, 2008). If left unchecked or mis-
activated, the inflammatory process can become pathogenic. This is true in SAH, when 
free hemoglobin (as a result of RBC lysis) are recognized and bound by TLR4s on the 
tissue-resident macrophages (Figueiredo et al., 2007; Hanafy, 2013; Lin et al., 2012). 
 In fact, inflammation due to over-active M1 macrophages has been implicated in 
several neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, 
MS and glioma, as well exacerbate neuronal injuries in traumatic brain injury and 
ischemic stroke (Hu et al., 2012; Saijo & Glass, 2011; G. Wang et al., 2013).  
 
M2 Macrophages 
On the other end of the spectrum, the alternatively activated M2 macrophages are 
the principal mediator for tissue repair. As with M1 macrophages, M2 macrophages can 
be induced by a wide range of stimuli, including T-helper cells, B cells, other 
macrophages, granulocytes, anti-inflammatory cytokines (such as IL-4, IL-13, and IL10), 
macrophage colony stimulating factor (M-CSF), glucocorticoid (Martinez & Gordon, 
2014), transforming growth factor-β (TGF-β), and some of the DAMP receptors (Mills & 
Ley, 2014). M2 macrophages promote resolution of injury by two mechanisms: first by 
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release of growth factors (such as TGF-β and vascular endothelial growth factor (VEGF)) 
to promote collagen synthesis and angiogenesis, or by increasing production of anti-
inflammatory cytokines to suppress immune response and induce clonal expansion of M2 
macrophages (Lamagna, Aurrand-Lions, & Imhof, 2006). In addition, M2 macrophages 
aide the healing process by upregulating arginase expression, effectively switching the L-
arginine metabolism from NO production to ornithine production. Ornithine is an 
important precursor for polyamines that are essential in cell proliferation and 
extracellular matrix repair (Mosser & Edwards, 2008). 
Therefore, it is not surprise that M2 macrophages have been associated with 
favorable outcome in the context of stroke. Researchers have found similar 
neuroprotection by M2 macrophages in mouse model of cerebral ischemia (Hu et al., 
2012), spinal cord injury (Kigerl et al., 2009), and traumatic brain injury (G. Wang et al., 
2013). Furthermore, these experimental models also show macrophages express transient 
M2 characteristics which peak in the first week, and sustained M1 characteristics that 
persist after 14 days. This suggest that rather than a mutually exclusive relationship, the 
two subpopulations of macrophages works in conjunction with each other, and their 
relative ratio may determines neuroprotection or neuronal injury outcome.  
One of the possible mechanisms which M2 macrophages exert its neuroprotection 
is through the resolution of the hemorrhage. CD163 is a haptoglobin-hemoglobin 
complex scavenger receptor found on M2 macrophages (Kristiansen et al., 2001). When 
extravascular blood is lysed, free hemoglobin is immediately bound to an acute phase 
protein, haptoglobin, forming a complex in attempt to neutralize the oxidative stress. The 
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CD163-mediated endocytosis of the haptoglobin-hemoglobin complex therefore plays a 
crucial role in the clearance of blood (Weaver, Pioli, Wardwell, Vogel, & Guyre, 2007). 
In abdominal aortic aneurysm, (Kristiansen et al., 2001) and atherosclerotic intraplaque 
hemorrhage (Finn et al., 2012), researchers have found that these CD163
+
 macrophages 
not only assist in erythrophagocytosis (the ingestion of blood), they also produce anti-
inflammatory cytokines and upregulate the expression of heme oxygenase-1 (HO-1) 
(Abraham & Drummond, 2006), which is an essential enzyme for breaking down heme 
into biliverdin, iron, and carbon monoxide. In addition, during the acute inflammatory 
response, surface CD163 of activated macrophages are enzymatically cleaved by matrix 
metalloproteinases (MMPs) into a soluble form called sCD163 (Sulahian, Hintz, 
Wardwell, & Guyre, 2001). CD163 also participates in the innate immune system as 
demonstrated in several studies; selective activations of TLRs by known agonists (such as 
lipopolysaccharide (LPS) for TLR4, zymosan for TLR2/6, Pam3Cys for TLR2/1, and S. 
typhimurium flagellin for TLR5) induce an acute shedding of CD163 (Burdo et al., 2011; 
Weaver et al., 2006; Weaver et al., 2007). As one would expect, a study finds that 
sCD163 increased dramatically in the CSF of SAH patients. The study also finds the free 
haptoglobin level is detectable despite showing high level of free hemoglobin, suggesting 
the CNS’s capacity to tolerate blood burden is dependent on CD163-haptoglobin-
hemoglobin scavenging system, with the CD163 expression on macrophages being the 
limiting factor (Galea et al., 2012).  
Most recently, our lab has established the neuroprotective role of the tissue-
resident macrophages via erythrophagocytosis in a mouse SAH model. The present thesis 
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is an extension of Hanafy (2015) and attempt to assess the in vivo activation state of the 
blood-activated macrophages in SAH patients, and its association with clinical outcome.   
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METHODS  
I have been given full permission by Dr. Khalid Hanafy to describe any protocols 
that his lab has either designed or edited for optimization. Credit has been given when 
appropriate. Methods described are based on Dr. Hanafy (2013, 2015) and unpublished 
protocols. 
 
Study Approval 
Patient consent forms and the study protocol were approved by the Institutional 
Review Board (IRB) of Beth Israel Deaconess Medical Center.  The protocol allows for 
collection of blood and CSF on days 1 and 7 of SAH patient admission.  Either the 
patient or a legal representative of the patient must sign the IRB approved consent before 
sample collection can occur.   
 
Human Sample Collection and Analysis 
Patients admitted to the neuro-intensive care unit (N-ICU) at Beth Israel 
Deaconess Medical Center in Boston, Massachusetts were recruited to the study based on 
the following criteria: 1) patients diagnosed with SAH, or 2) patients with un-ruptured 
cerebral aneurysm scheduled for surgical clipping or endovascular coiling embolization. 
Approximately 20-30cc of CSF sample was acquired from each patient on day 1 and day 
7. CSF of SAH patients was obtained via EVD, and CSF of unruptured aneurysm patients 
was obtained at the time of the surgery. 
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Twenty-five total patients were enrolled to the study (n=25); two patients with 
SAH were excluded because patients’ conditions did not allow for CSF collection 
through EVD. In total, seven patients with SAH were included in this study, including 
four males and three females (n=7, Table 2). Sixteen patients with unruptured aneurysm 
were included in this study as the control group, including four males and twelve females 
(n=16, not shown). 
 
Table 2. Demographic and clinical characteristic of SAH patients 
Patient # Age Sex Hunt & Hess 
Grade 
Fisher 
Grade 
Modified 
Rankin Scale 
Procedure 
1 50 M 4 4 3 Coil 
2 63 M 5 2 6 Coil 
3 78 F 3 3 6 Coil 
4 58 F 5 3 5 Coil 
5 51 M 2 1 2 Coil 
6 72 M 5 4 5 Coil 
7 42 F 3 2 3 Clipped 
 
CSF was centrifuged at 1850 rpm for five minute. Cell free fluid was collected in 
15ml conical tubes and stored at -80°C for future analysis. The cell pellet was incubated 
with 1x RBC lysis buffer (Biolegend) for five minutes on ice. Cells were washed, and re-
suspended in FACS buffer (PBS with 1% BSA, 2mM EDTA and 0.05% Na-azide) for 
flow cytometry analysis.  
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Flow Cytometry 
The cells harvested from CSF of enrolled patients were washed and re-suspended 
in 200ul of FACS buffer. Cells were pre-blocked with Human TruStain FcX Fc-receptor 
blocker at 5:100 (Biolegend) for 10 minutes. Without washing, cells were incubated for 
30 minutes, on ice with slow rocking, with the following antibodies (5:100):  
1. Mouse IgG antibody conjugated to a PE fluorophore against human CD163 
(Biolegend), which is a surface scavenger receptor expressed on M2 
macrophages. 
2. Mouse IgG antibody conjugated to a Pe/Cy7 fluorophore against human CD15, a 
cell surface receptor expressed exclusively on polymorphonuclear neutrophils 
(PMNs) in patients without lymphoma. 
3. Mouse IgG antibody conjugated to an APC fluorophore against human CD14, a 
cell surface receptors highly expressed on monocytes and macrophages.  
Acquisition of cells was performed on a FACSCalibur (BD Biosciences, San Jose, 
CA), and data were analyzed with FlowJo software (Tree Star Inc.).  
 
Hunt and Hess Scale 
 SAH patients were graded by the N-ICU medical team upon admission based on 
clinical presentation of the sickness. The following grading scale was adopted from 
Medscape.com (Tjoumakaris & Dalyai, 2014): 
Grade 1: Asymptomatic or mild headache 
Grade 2:  Cranial nerve palsy or moderate to severe headache/nuchal rigidity 
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Grade 3:  Mild focal deficit; lethargy, or confusion 
Grade 4: Stupor and/or hemiparesis 
Grade 5: Deep coma, decerebrate posturing, moribund appearance 
 
Modified Fisher Scale 
 SAH patients were graded upon admission based on the severity of the 
hemorrhage as seen on CT. The following grading scale was adopted from 
Medscape.com (Klimo Jr. & Schmidt, 2006): 
Grade 0: no SAH or intraventricular hemorrhage (IVH) 
Grade 1:  minimal/thin SAH, no IVH in both lateral ventricles 
Grade 2: minimal/thin SAH, with IVH in both lateral ventricles 
Grade 3: thick SAH, no IVH in both lateral ventricles 
Grade 4:  thick SAH, with IVH in both lateral ventricles 
 
 
Modified Rankin Scale 
 Clinical outcome in SAH patients was measured based on the disability or 
dependency of the patient at the time of discharge as compared to his/her pre-SAH state. 
The following scale was adopted from Medscape.com (Christensen, 2014): 
Score 0:  No symptom at all 
Score 1:  Significant disability despite symptoms; able to carry out all usual duties 
and activities 
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Score 2: Slight disability; unable to carry out all previous activities; but able to look 
after own affairs without assistance 
Score 3: Moderate disability; requiring some help, but able to walk without 
assistance 
Score 4: Moderately severe disability; unable to walk without assistance and unable 
to attend to own bodily needs without assistance 
Score 5:  Severe disability; bedridden, incontinent and requiring constant nursing 
care and attention 
Score 6:  Dead 
 
Statistical Analysis 
 Continuous variables were assessed for normality with skewness and kurtosis. All 
variables measured in this study were normally distributed. The control group and SAH 
day 1 group were assessed by a two-tailed Student’s non-paired t-test, and SAH day 1 
group and the SAH day 7 group were assessed by the Student’s paired t-test. All 
statistical analyses were performed using Prism Software for window. P<0.05 were 
considered statistical significant (Hanafy, 2013) 
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  RESULTS 
 
SAH induced increase CD14+ macrophage population 
FACS data were analyzed on seven SAH patients and sixteen control patients 
with unruptured aneurysm using FlowJo software.  Macrophage population is separated 
from other immune cells based on three antibodies: CD14, CD15 and CD163. First, a 
viable leukocyte population is gated based off the forward light scatter versus the side 
scatter to exclude debris and dead cells. Next, macrophages are identified by 
CD14
+
/CD15
-
 expression. Figure 1A shows that the CD14
+
/CD15
-
 macrophage 
population in SAH patients increases significantly on day 1 when compared to the control 
group (n=23, p<0.05). In addition, the macrophage population also increases from day 1 
to day 7 in SAH patients (n=7, p<0.1) (Figure 1A). Positive CD163 expression is 
identified based off an unstained sample and a fluorescence-minus-one sample (FMO), 
which is a sample from the same patient stained with PeCy7 anti-CD15 and APC anti-
CD14 minus Pe anti-CD163 antibodies (Figure 2A). 
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Figure 1. Myeloid-lineage cell populations in SAH and control patients. 
Macrophages are identified by CD14
+
/CD15
-
 expression and polymorphonuclear 
neutrophils (PMNs) are identified by CD15
+
 expression. (A) The macrophage population 
significantly increases on day 1 SAH patients as compared to control patients (2-tailed 
Student’s t test; n=23, p<0.05); and increases from day 1 to day 7 in SAH patients (2-
tailed Student’s paired t test, n=7, p<0.1). (B) PMN population increases significantly in 
day 1 SAH patients as compared to control patients (2-tailed Student’s t test; n=23, 
p<0.05); but shows a downward trend on day 7 when compared with day 1 in SAH 
patients (2-tailed Student’s paired t test, n=7, p>0.05).  
 
 Despite a significant increase in the CD14
-
/CD15
+
 polymorphonuclear neutrophil 
(PMN) population in SAH patients on day 1 when compared to the control group 
(p<0.05), the PMN population shows a downward trend on day 7 when compared to day 
1 in SAH patients  (Figure 1B). Further analysis of PMNs from SAH patients reveals 
negligible CD163 expression (Figure 2B). Therefore, we will exclude PMNs from further 
discussion.  
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Figure 2. CD163 expression on human CSF macrophages and PMNs in SAH 
patient. 
Representative dot plots of macrophages (CD14
+
/CD15
-
) and PMNs (CD14
-
/CD15
+
) 
showing their corresponding CD163 expression. The representative sample was obtained 
from the CSF of a SAH patient on (A) day 1, and (B) day 7. Gates are drawn based off an 
unstained sample and a FMO sample from the same patient.  
 
 
Macrophage CD163 expression increases from day 1 and day 7 in SAH 
patients  
 
Next, we examine the macrophage CD163 expression in the CSF of SAH day 1 
patients (n=7) in comparison to the control group (n=16). The macrophage CD163 
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expression increases significantly in day 1 SAH patients when compared to the control 
group (Figure 3B, p<0.05). Furthermore, there is an upward trend in macrophage CD163 
expression on day 7 as compared to day 1 in SAH patients (p>0.05).  
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Figure 3. Human macrophage CD163 expression increases on in SAH patients. 
A) Day 1 and day 7 SAH patients show a significant increase in macrophage CD163 
expression as compared to the control group (2-tailed Student’s t test, n=23, 
p<0.05).There is an upward trend in the macrophage CD163 expression between day 1 
and day 7 samples in SAH patients (2-tailed Student’s paired t test, n=7, p>0.05) 
 
 In previous unpublished mouse studies, our lab has observed a difference in the 
immune-response to SAH between genders. To account for this confounding variable, 
SAH patients are separated by their gender and analyzed for their macrophage CD163 
expression (Figure 4). On day 1, macrophage CD163 expression in male SAH patients is 
equivocal to those in male control patients (Figure 4A, p>0.05), but the expression 
increases significantly on SAH day 7 as compared to SAH day 1 (p<0.01). On the other 
hand, macrophage CD163 expression in female SAH patients significantly increases on 
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day 1 (p<0.001) when compared to the control group (Figure 4B), but there may be a 
downward trend on day 7 SAH when compared to day 1 in these same patients (p>0.1). 
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Figure 4. Macrophage CD163 expression based on genders. 
(A) Macrophage CD163 expression in male SAH patients on day 1 is equivocal to the 
control group (2 tailed Student’s t test; n=8; p>0.1); but demonstrates a significantly 
higher expression on day 7 as compared to day 1 (2-tailed Student’s paired t test, repeated 
measures; n=4, p<0.01) and the control group (2-tailed Student’s t test; n=8, p<0.01); (B) 
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macrophage CD163 expression in female SAH patients on day 1 is significantly higher 
than those of the control group (2-tailed Student’s t test; n=14, p<0.001), but shows a 
decrease trend on day 7 post-ictus (2-tailed Student’s t test, repeated measures; n=3, 
p>0.1) 
 
Increase in blood burden causes decrease of surface CD163 expression in 
macrophages 
 
Blood burden in a SAH can be defined by the size of the hemorrhage (measured 
by modified Fisher scale) and the extent of injury caused by such hemorrhage (measured 
by Hunt and Hess scale). To test the hypothesis that CD163
+
 macrophages play an 
essential role in alleviating the blood burden after SAH, the CD163
+
 macrophage 
population in SAH patients on day 1 is plotted against the modified Fisher scale and the 
Hunt and Hess scale. The result shows a potential trend that as the size of the bleed 
increases, macrophage CD163 expression in SAH day 1 patients decreases (Figure 5A). 
The same potential trend is less apparent when macrophage CD163 expression in SAH 
day 1 patients is plotted against the Hunt and Hess scale (Figure 5B). Due to the small 
sample size, more SAH patients are required to establish correlation.  
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Figure 5. Macrophage CD163 expression in SAH day 1 patients may correlate with 
blood burden. 
Macrophage CD163 expression may show an inverse trend against the A) modified 
Fisher Scale; and B) Hunt and Hess grade. Sample size is not sufficiently large to 
perform a Spearman’s test. 
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Macrophage CD163 expression affects clinical outcome in SAH patients 
We compare the macrophage CD163 expression on day 1 and day 7 in SAH 
patients to their corresponding clinical outcome at the time of discharge, which is 
measured by the modified Rankin Scale (mRS). The results show an interesting temporal 
relationship between the macrophage CD163 expression in SAH day 1 and day 7 patients 
and clinical outcome.  In the SAH patient group, individual with poorer outcome (marked 
by higher mRS score) tends to have higher macrophage CD163 expression on day and 
day 7 as compared to patient with lower mRS score (Figure 6). Due to the small sample 
size, a Spearmen’s test cannot be performed to conclude correlation between macrophage 
CD163 expression and clinical outcome.  
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Figure 6. Macrophage CD163 expression may correlate with clinical outcome as 
measured by mRS score in SAH patients. 
SAH patient with poorer clinical outcome (marked by higher mRS score) has higher 
CD163 expression on day 1 and day 7 as compared to patient with better clinical 
outcome. 
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 In previous analysis, we have discovered an overall gender-based difference in 
macrophage CD163 expression in response to SAH. This gender difference is further 
analyzed in relation to the clinical outcome.  All male SAH patients (n=4) show higher 
CD163 expression on day 7 as compared to day 1 (Figure 7A); while all female SAH 
patients show lower macrophage CD163 expression on day 7 as compared to day 1 
(Figure 7B). There may be a correlation between clinical outcome and the rate of change 
in CD163 expression from day 1 to day 7 SAH. In male SAH patients, the rate of 
increase in macrophage CD163 expression appears to be independent of clinical 
outcome; while in female SAH patients, patient with lower decrease in macrophage 
CD163 expression has poorer clinical outcome.  
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Figure 7. Changes in macrophage CD163 expression are gender-dependent, and 
may be correlated with clinical outcome. 
A) CD163 expression in macrophages increases on day 7 as compared to day 1 in all 
male SAH patients, and B) CD163 expression in macrophages decreases on day 7 as 
compared to day 1 in all female SAH population. 
 
Our results have several implications: 1) macrophages differentiate and proliferate 
to the CD163
+
 M2 phenotype in response to SAH, and the response may be proportional 
to the extent of blood burden; 2) macrophage CD163 expression in SAH patient may 
potentially be used as an early prognostic tool to predict outcome, 3) CD163
+
 
macrophages may be directly involved in alleviating neuronal injury due to 
neuroinflammation, and 4) there is a gender difference in the cerebral immune response 
in SAH patients.   
 38 
DISCUSSION 
 
When an aneurysm bursts in the SAS, RBCs lyses and release hemoglobin to 
initiate a sterile cerebral inflammatory response. The free hemoglobin initiates the 
generation of free radicals and activates the innate immune system in hemorrhagic 
events. Our lab has identified macrophages to be essential in mediating both neuronal 
injury and neuroprotection in a mouse SAH model (Hanafy, 2013; Schallner et al., 2015) 
The blood-induced neuroinflammation starts when free hemoglobin is recognized 
and bound by TLR4s expressed on macrophages. TLR4 activation will drive 
macrophages toward M1 phenotype (N. Wang, Liang, & Zen, 2014). These M1 
macrophages has been shown to be responsible for induction of neuronal injury in mouse 
SAH model (Hanafy, 2013). CD14 is a TLR4 co-receptor that is highly expressed on 
monocytes and macrophages. Although recent studies show that CD14 is also expressed 
in granulocytes, dendritic cells, lymphocytes, and some non-myeloid linage cells such as 
endothelial and epithelial cells, the expression is ten times lower in these cells in 
comparison to macrophages (Jersmann, 2005). This co-receptor for TLR4 is crucial for 
the recognition and binding of LPS in TLR4 mediated endocytosis; and during 
inflammation, CD14 expression is upregulated in macrophages (Zanoni et al., 2011). Our 
analysis of the CD14
+
 macrophage population reveals that SAH patients have a much 
higher CD14
+
 macrophage population on day 1 and day 7 as compared to the control 
group. This result suggests that there is an upregulation of TLR4 in response to 
hemoglobin binding, and further supports our previous observations in animal SAH 
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model that the TLR4 expressing macrophages may play an important role in mediating 
neuroinflammation, which is absent in the control patients.  
On the other hand, macrophages with M2 phenotype have been proposed to exert 
neuroprotection in cerebral injury by suppressing the neuroinflammation through 
increased production of anti-inflammatory cytokines. However, macrophages with an M2 
phenotype may serve another anti-inflammatory function via their enhanced capacity for 
erythrophagocytosis. In our mouse SAH model, neuroprotection by CNS macrophages is 
mediated through the expression of heme oxygenase-1, which can be induced by the 
CD163-mediated erythrophagocytosis (Abraham & Drummond, 2006; Schallner et al., 
2015). The hemoglobin-haptoglobin complex scavenger receptor called CD163 is one of 
the defining characteristics for M2 macrophages. In acute inflammation, the TLR4 
cascade can activate MMPs which cleave CD163 into its soluble form sCD163 within 
hours (Weaver et al., 2006). This process can be measured by a significant increase of 
sCD163 in the serum and significant decrease in CD163 expression on macrophages 
(Burdo et al., 2011). In addition, the activation of TLRs can induce the upregulation of 
CD163 expression during the later phase of inflammation on active macrophages as 
compared to quiescent macrophages (Burdo et al., 2011; Weaver et al., 2006; Weaver et 
al., 2007). We propose that macrophages with M2 phenotype exert neuroprotection by 
eliminating free hemoglobin via the CD163-mediated erythrophagocytosis; and we 
hypothesize the expression of this scavenger receptor is correlated with clinical outcome 
in SAH patients.  
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We first show that the expression of macrophage CD163 is increased in SAH 
patients. We have analyzed twenty-three CSF samples, and conclude the two major 
myeloid cell populations present in CSF of a SAH patient are macrophages and PMNs. 
Despite a massive influx of the PMN population on SAH day 1 (Figure 1B), CD163 
expression on PMNs is negligible as compared to its expression on macrophages (Figure 
2B).  
Next, we analyze the levels of CD163 expression on macrophages in SAH 
patients and the control group. Figure 3 shows the expression of CD163 significantly 
increases on day 1 as compared the control group; and there is an upward trend on day 7 
from day 1, though such increase is not significant. Since the control group had 
undergone a more invasive surgical procedure than the majority of the SAH patients 
(Table 2), the result suggests that the significant increase in macrophage CD163 
expression in SAH day 1 may be independent of surgical procedure. The relatively low 
CD163 expression on SAH day 1 as compared to SAH day 7 may indicate the active 
shedding of CD163 into sCD163 on macrophages in response to the acute inflammation, 
since surface CD163 expression on macrophages is inversely proportional to the 
concentration of sCD163. This phenomenon has been published by another study 
conducted by Galea et al., where sCD163 concentration in CSF increased dramatically 
after SAH due to the shedding of CD163 in CNS macrophages. This hypothesis is further 
supported when macrophage CD163 expression on day 1 is plotted against the modified 
Fisher scale. The result shows that SAH patients with more severe hemorrhages have 
lower surface CD163 expression on day 1 (Figure 5A & 5B). These results suggest that 
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the active shedding of CD163 on macrophages may be correlated to the blood-induced 
inflammation and is proportional to the size of the bleed. However, more patient samples 
are required before correlation can be established. 
The increase of CD163 expression in macrophages on SAH day 7 may be the 
direct result of an activated innate immune response. Researchers have shown that 
activation of TLR4 by LPS can induce upregulation of CD163 on macrophages in the 
later phase of inflammation (Weaver et al., 2007). The upward trend of CD163 
expression combined with an increase of CD14 expression in macrophages, may indicate 
the blood-induced inflammation share some similar cellular pathways in the classical 
TLR4 activation by LPS. 
The increased CD163 expression in macrophages may be beneficial to clinical 
outcome as CD163
+
 macrophages exhibit enhanced capacity for erythrophagocytosis 
(Schaer, Schaer, Schoedon, Imhof, & Kurrer, 2006). Not surprisingly, the levels of 
macrophages CD163 expression at different time in the progression of SAH may have 
profound effect on the patient outcome. Figure 6 shows that patients with poorer clinical 
outcome (marked by high mRS score) have higher macrophage CD163 expression on 
SAH day 1 and day 7. Furthermore, the result shows SAH patients with poorer clinical 
outcome have smaller change in CD163 expression between day 1 and day 7. The 
underlying mechanism may be explained by the multiple roles of CD163 played during 
an inflammation.  In the early phase of the hemorrhage, lower CD163 expression may be 
indicative to a faster response to cleave their CD163 surface receptors in a SAH patient. 
The soluble form sCD163 can therefore quench any unbound hemoglobin and facilitate 
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its elimination from the CNS in shorter period of time, therefore removing the stimulus 
for acute inflammation. On day 7 of SAH, higher macrophage CD163 expression 
corresponds to a higher capacity for erythrophagocytosis as well as production of anti-
inflammatory cytokines such as IL-10 to suppress inflammation (Abraham & 
Drummond, 2006; Moestrup & Moller, 2004). The combined temporal effects of the 
CD163
+
 macrophage population in the CNS may therefore be critical in determining a 
patient’s outcome.  
Upon closer examination, we discover a gender-based differential in macrophage 
CD163 expression. Gender has been known to play a significant role in the incidence and 
clinical outcome in SAH. In general, women are twice as likely to have a SAH, have 
double the mortality rate, and have a higher recurrence rate and poorer quality of life after 
SAH (Hamdan, Barnes, & Mitchell, 2014). Such disparities may be linked to the CD163 
expression in macrophages during the inflammatory timeline.  
Analysis shows that female patients have higher macrophage CD163 expression 
on day 1 as compared to male patients (Figure 4A & 4B). Since macrophage CD163 
expression on day 1 is inversely proportional to sCD163, the result indicates that female 
patients have lower capacity to eliminate excess hemoglobin from the SAS, and therefore 
may experience a more severe blood-induced inflammation. In addition, while all male 
SAH patients have increased macrophage CD163 expression on day 7 as compared to 
day 1, in female SAH patients the expression decreases significantly on day 7 as 
compared to day 1. The increase in male patients’ macrophage CD163 expression on day 
7 suggests their macrophages may have higher capacity of M2 differentiation and 
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proliferation, or they are able to sustain a M2 phenotype longer than female SAH 
patients. These changes may potentially be a contributing factor to clinical outcome in 
SAH patients because the CD163-induced M2 phenotype has been shown to release the 
anti-inflammatory cytokine IL-10 and upregulate expression of HO-1. The combined 
effects of these mechanisms may allow for a more effective elimination of excess blood 
in SAS and better suppression of the inflammatory response in SAH. 
Furthermore, clinical outcome in male SAH patients appears to be independent 
from the rate of change in macrophage CD163 expression between day 1 and day 7. On 
the other hand, a smaller decrease in macrophage CD163 expression may result in poorer 
clinical outcome among female SAH patients. The difference in the change of 
macrophages expression between genders is worthy of further investigation, as it may 
potentially be the underlying mechanism that contribute to the higher mortality and 
morbidity in female SAH patients. In conclusion, macrophages in SAH patients exhibit 
dual-functions that may affect clinical outcome. Macrophages exhibit increased M1 
phenotype (marked by CD14, the co-receptor for TLR4) and M2 phenotype (marked by 
CD163) simultaneously in response to SAH. Furthermore, gender and CD163 expression 
in macrophages may be used as a prognostic tool for clinicians to predict clinical 
outcome in SAH patients. However, more patients are required to account for age, 
gender, Hunt and Hess score, modified Fisher score and history of smoking.  
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Worked as a research student under the tutelage of Dr. Khalid Hanafy to study the 
pathophysiological mechanisms of Subarachnoid Hemorrhage (SAH). Research 
interests include the role of the innate immune system played in the progression of the 
disease and its contribution to clinical features such as neuroinflammation, delay 
cerebral ischemia, neuronal injury and cognitive deficits by using a mouse SAH 
model; the study of biomarker(s) expression in cerebrospinal fluid (CSF) of 
aneurysmal SAH patients and establish correlation to clinical outcome. Lab duties are 
listed as followed:  
 
 Clinical Research 
o Process CSF samples 
o Cell surface and intracellular fluorescence staining of primary human 
CSF cells 
o Fluorescence-activated cell sorting 
o Viability Assay and Spectrophotometer use 
o Primary human CSF cells plating 
 
 Animal Research (in vivo): 
o General study of transgenic and wild type mice 
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o Studying of primary mouse microglia of different genotypes, BV2 cell 
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